Amicus fail dents Pompe pipeline
Amicus follows Sanofi with disappointing pivotal Pompe data, casting further doubt on approvals.
Gilead’s Galapagos hopes now rest on Toledo
Toxicity worries send yet another Gilead/Galapagos project, ziritaxestat, to the scrapheap.
Cholesterol fears rock Immunovant
Immunovant and other FcRn-players must hope that a potential safety signal turns out to be indication rather than class specific.
Merck’s Covid-19 vaccines head for the scrapheap
Merck & Co’s move illustrates how hard it will be for the second wave of Covid-19 vaccine candidates to succeed.
Merck KGaA’s dual immuno-oncology weapon misfires
Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.
The pandemic releases its grip on clinical trials
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
Biohaven pops the Alzheimer’s bubble
Troriluzole has failed in an Alzheimer’s trial, reminding the markets that this is par for the course in this disease.
